NASDAQ:ACIU - AC Immune Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.21 +0.20 (+4.99 %) (As of 02/21/2019 09:08 AM ET)Previous Close$4.01Today's Range$4.01 - $4.2752-Week Range$3.25 - $17.40Volume344,717 shsAverage Volume1.21 million shsMarket Capitalization$277.27 millionP/E Ratio-14.03Dividend YieldN/ABeta-0.09 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland. Receive ACIU News and Ratings via Email Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACIU Previous Symbol CUSIPN/A Webwww.acimmune.com Phone41-21-345-9121Debt Debt-to-Equity RatioN/A Current Ratio19.22 Quick Ratio19.22Price-To-Earnings Trailing P/E Ratio-14.03 Forward P/E Ratio-421.00 P/E GrowthN/A Sales & Book Value Annual Sales$15.58 million Price / Sales17.80 Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book2.01Profitability EPS (Most Recent Fiscal Year)($0.30) Net Income$-26,840,000.00 Net Margins-146.09% Return on Equity-24.14% Return on Assets-21.48%Miscellaneous Employees86 Outstanding Shares65,860,000Market Cap$277.27 million OptionableNot Optionable AC Immune (NASDAQ:ACIU) Frequently Asked Questions What is AC Immune's stock symbol? AC Immune trades on the NASDAQ under the ticker symbol "ACIU." How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The firm had revenue of $2.34 million for the quarter, compared to the consensus estimate of $1.71 million. AC Immune had a negative net margin of 146.09% and a negative return on equity of 24.14%. View AC Immune's Earnings History. When is AC Immune's next earnings date? AC Immune is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for AC Immune. What price target have analysts set for ACIU? 4 brokers have issued 12 month price targets for AC Immune's shares. Their forecasts range from $8.00 to $18.00. On average, they expect AC Immune's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 232.5% from the stock's current price. View Analyst Price Targets for AC Immune. What is the consensus analysts' recommendation for AC Immune? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune. What are Wall Street analysts saying about AC Immune stock? Here are some recent quotes from research analysts about AC Immune stock: 1. According to Zacks Investment Research, "AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. " (2/12/2019) 2. HC Wainwright analysts commented, "We hosted a management breakfast (January 9, 2019) in the JPM (JPM; not rated) healthcare conference with AC Immune’s CEO, Andrea Pfeifer. During the discussions with management, a key focus from investors was on the interim analysis of crenezumab’s CREAD1 Phase 3 trial this year, and the role of effector function in targeting mis-folded proteins in the brain. We have limited clarity on the timing or the type of crenezumab’s interim analysis based on the conversations with management, and believe that this event remains a critical inflection point for the company. We think that the updated BAN2401 and aducanumab data collectively lend support to amyloid hypothesis and should have positive read-through to crenezumab." (1/24/2019) Has AC Immune been receiving favorable news coverage? Headlines about ACIU stock have trended positive on Thursday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AC Immune earned a news impact score of 2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of AC Immune's key competitors? Some companies that are related to AC Immune include Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Tricida (TCDA), Kiniksa Pharmaceuticals (KNSA), Alder Biopharmaceuticals (ALDR), MacroGenics (MGNX), CannTrust (CNTTF), Homology Medicines (FIXX), Advanz Pharma (CXRXF), Retrophin (RTRX), Radius Health (RDUS), Athenex (ATNX) and ImmunoGen (IMGN). Who are AC Immune's key executives? AC Immune's management team includes the folowing people: Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)Mr. Joerg Hornstein, Chief Financial Officer (Age 40)Mr. Piergiorgio Donati, Head of Technical Operations & Program ManagementDr. Marie Kosco-Vilbois, Chief Scientific OfficerMr. Jean-Fabien Monin, Chief Admin. Officer (Age 48) When did AC Immune IPO? (ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. Who are AC Immune's major shareholders? AC Immune's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.98%), Sphera Funds Management LTD. (0.47%), Alps Advisors Inc. (0.24%), Essex Investment Management Co. LLC (0.06%), Cohen Lawrence B (0.02%) and Squarepoint Ops LLC (0.02%). Which institutional investors are selling AC Immune stock? ACIU stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Cohen Lawrence B. Which institutional investors are buying AC Immune stock? ACIU stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Alps Advisors Inc., Essex Investment Management Co. LLC, Squarepoint Ops LLC and Barclays PLC. How do I buy shares of AC Immune? Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AC Immune's stock price today? One share of ACIU stock can currently be purchased for approximately $4.21. How big of a company is AC Immune? AC Immune has a market capitalization of $277.27 million and generates $15.58 million in revenue each year. The company earns $-26,840,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. AC Immune employs 86 workers across the globe. What is AC Immune's official website? The official website for AC Immune is http://www.acimmune.com. How can I contact AC Immune? AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected] MarketBeat Community Rating for AC Immune (NASDAQ ACIU)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 155 (Vote Outperform)Underperform Votes: 154 (Vote Underperform)Total Votes: 309MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of buying treasury bonds?